TILT Biotherapeutics: TILT Biotherapeutics Presents Clinical Data on TILT-123

HELSINKI, Sept. 09, 2024 (GLOBE NEWSWIRE) - TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present data at the European Society of Medical Oncology (ESMO) Congress 2024. The results further demonstrate the potential for TILT-123 as an intravenous therapy. The data presented covers the results of a Phase I [...]